In a significant step forward for clinical trial innovation, TrialKey (ASX: OPL) has entered into a Service Level Agreement (SLA) with Southern Clinical Development Consulting (Southern CDC). This strategic partnership leverages Opyl’s AI-driven TrialKey platform to enhance Southern CDC’s capabilities in clinical trial support and optimisation. The agreement underscores both companies’ commitment to advancing drug development through innovative, data-driven solutions.
Revolutionising Clinical Trials with Data-Driven Insights
Opyl’s TrialKey platform brings a suite of AI-powered tools to support Southern CDC’s mission of facilitating efficient and precise clinical trials. Under this agreement, Opyl will provide bespoke reports tailored to each project, delivering insights that shape trial design, feasibility, and patient recruitment strategies.
Key Highlights of the Partnership:
- AI-Driven Reports: Opyl’s TrialKey platform generates predictive modelling and validation reports, enabling informed decision-making during trial design and planning phases.
- Flexible Revenue Model: Opyl will earn a fee for each report delivered, with pricing adaptable to the scope of services required.
- Enhanced Trial Design: TrialKey assists in refining trial protocols, site selection, and patient enrolment strategies, ensuring trials are optimised for success.
- Strategic Sector Impact: This partnership reinforces Opyl’s growing influence in clinical trial support, aligning with Southern CDC’s aim to accelerate patient access to innovative therapies.
Scope of AI-Driven Reporting
The TrialKey platform delivers comprehensive, data-enriched reports tailored to the specific needs of each trial, including:
- Predictive Modelling & Validation: AI simulations refine trial designs by analysing large datasets, predicting outcomes with greater accuracy.
- Competitor Analysis: In-depth reviews of similar trials guide strategic positioning and optimise trial execution.
- Risk & Feasibility Assessment: Detailed site analysis identifies optimal locations while minimising risks.
- Patient Recruitment Strategies: AI insights streamline enrolment processes, improving efficiency and retention.
These capabilities equip Southern CDC with the tools needed to enhance trial planning and execution, directly addressing challenges such as site selection and patient recruitment.
Executive Insights
Saurabh Jain, Executive Chairman, Opyl Limited:
“We’re delighted to see Southern CDC integrate TrialKey into their operations. This partnership reflects our broader vision to collaborate with CROs worldwide and position TrialKey as a cornerstone of modern clinical trial management. By delivering actionable, data-driven insights, TrialKey supports CROs and their clients in achieving faster, more efficient trials.”
Dr Khalid Abubaker, Chief Operating Officer, Southern CDC:
“TrialKey represents a transformative tool for clinical trial management. At Southern CDC, we’re committed to refining drug development and patient care. TrialKey’s advanced analytics empower us to accelerate trial timelines while addressing patient needs with precision. Together with Opyl, we aim to bring life-changing treatments to market faster, where every day truly matters.”
A Shared Mission to Advance Medical Innovation
Southern CDC, renowned for its expertise across therapeutic areas such as oncology, immunology, neurology, ophthalmology, and infectious diseases, will integrate TrialKey into its suite of services. This collaboration will enhance their ability to support sponsors through efficient and agile trial planning.
The Future of Clinical Trials
The SLA establishes Opyl as an independent contractor for an initial six-month term, with potential extensions by mutual agreement. This partnership paves the way for further integration of AI-driven platforms in clinical trial management, setting a precedent for innovation in the sector.
By combining Southern CDC’s expertise with Opyl’s cutting-edge technology, this collaboration marks a milestone in clinical trial optimisation—ultimately accelerating the delivery of life-changing treatments to patients worldwide.
About Southern Clinical Development Consulting (Southern CDC):
Southern CDC is a leading clinical development service provider, supporting drug development from pre-clinical stages to late-phase trials. With a focus on oncology, ophthalmology, immunology, and neurology, Southern CDC delivers strategic consultancy and operational support to sponsors, enabling efficient trial execution and patient-centred care.
This partnership represents a new era in clinical trial innovation, underscoring the power of AI to drive meaningful change in the healthcare landscape. With TrialKey at the forefront, Opyl and Southern CDC are poised to redefine the future of clinical trials.
Discover how TrialKey can transform your next project. Book a demo with us today.
